SMO and nevoid basal cell carcinoma syndrome: Patidegib exhibits its pharmacological effect by inhibiting SMO [20], and received approval as Orphan Drug Designation and Breakthrough Therapy Designation as topical gel in Gorlin syndrome both by FDA and EMA’s Committee for Orphan Medicinal Products in the EU in 2018 [21,22].